Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych: monotherapy

Sortuj według:

Ogranicz wyniki do:

Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication

100%

Walencka E., Sadowska B., Rozalska S., Hryniewicz W., Rozalska B.

Polish Journal of Microbiology

2005

tom 54

nr 3

The aim was to study the activity of lysostaphin in monotherapy or in combination with oxacillin, towards biofilms built by clinical and reference S. aureus and S. epidermidis strains in the wells of microplate, in the chambers of a LabTekII chamber slide or on the polyethylene catheter. MICs of oxacillin and lysostaphin for planktonie bacteria were determined according to the standards of NCCLS. BIC (Biofilm Inhibitory Concentration) was estimated by the MTT assay. The integrity of biofilm treated with antimicrobials was also examined: by staining with FITC and laser scanning fluorescence confocal microscopy and visually by TTC reduction assay. Despite the fact that susceptibility of planktonie cultures of 25 staphylococcal strains to lysostaphin action was various, we have demonstrated the effectiveness of lysostaphin in the treatment of biofilm, built not only on the flat surface of the microplates but also on catheter's surface. The synergistic effect of subBIC lysostaphin+oxacillin was observed forMSSA and MRSA biofilms but not for 1474/01 hVISA strain. Also BICOXA for S. epidermidis RP12 and A4c strains, but not for 6756/99 MRSE biofilms was reduced when lysostaphin was simultaneously used.

Cardiovascular effects of the combination of levosimendan and valsartan in hypertensive Dahl/Rapp rats

80%

Biala A., Finckenberg P., Korpi A., Loytainen M., Martonen E., Levijoki J., Mervaala E.

Journal of Physiology and Pharmacology

2011

tom 62

nr 3

Hypertension is the main risk factor for left ventricular hypertrophy and development of diastolic heart failure. There is no yet treatment, which can effectively reduce mortality in patients suffering from heart failure with preserved systolic function. We tested whether the calcium sensitizer levosimendan and the AT1-receptor antagonist valsartan could protect from salt-induced hypertension, cardiovascular mortality and heart failure in Dahl/Rapp salt-sensitive rats fed for 7 weeks with a high salt diet (8% NaCl). Levosimendan (1 mg/kg/day via drinking water) and valsartan (30 mg/kg in the food) monotherapies and their combination prevented mortality in Dahl/Rapp rats. The drug combination evoked an additive effect on blood pressure, cardiac hypertrophy, cardiomyocyte cross-sectional area, target organ damage and myocardial ANP mRNA expression. There was a close correlation between systolic blood pressure and cardiac hypertrophy, cardiac and renal damage. As compared to Dahl/Rapp controls kept on low-salt diet (NaCl 0.3%). The high salt rats exhibited impaired diastolic relaxation as assessed by isovolumic relaxation time. Levosimendan alone and in combination with valsartan, improved diastolic relaxation without significantly improving systolic function. Our findings are evidence for an additive effect between levosimendan and valsartan on blood pressure and a blood pressure- dependent protection against the development of salt-induced target organ damage. The present study also demonstrates that levosimendan, alone or in combination with valsartan, can correct diastolic dysfunction induced by salt-dependent hypertension.

Ograniczanie wyników

1 Journal of Physiology and Pharmacology

1 Polish Journal of Microbiology

1 Biala A.

1 Finckenberg P.

1 Hryniewicz W.

1 Korpi A.

1 Levijoki J.

1 Loytainen M.

1 Martonen E.

1 Mervaala E.

1 Rozalska B.

1 Rozalska S.

1 Sadowska B.

1 Walencka E.

1 2011

1 2005

Wyniki wyszukiwania

Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication

Cardiovascular effects of the combination of levosimendan and valsartan in hypertensive Dahl/Rapp rats